Target intelligence / Profile preview

Methyl group transfer pathway

Molecular classification
Other
01

Overview

Methyl group transfer pathways refer broadly to a set of interconnected biochemical cycles responsible for the transfer of methyl groups (–CH₃) to diverse substrates, including DNA, RNA, proteins (especially histones), and small molecules. These reactions are catalyzed primarily by *methyltransferases*, which use S-adenosylmethionine (SAM) as the universal methyl donor[1][2][3][4][5]. The methionine → SAM → S-adenosylhomocysteine (SAH) → homocysteine cycle is central to methyl group supply and recycling in cells, often termed the "SAM cycle" or one-carbon metabolism[1][3]. Methyl group transfer is crucial for epigenetic regulation, influencing gene expression, chromatin structure, and cellular differentiation[1][2][7]. Disruption of these pathways, whether by genetic variants or nutritional deficiencies (e.g., folate or vitamin B₁₂), has been linked to diseases such as cancer, neural tube defects, and neuropsychiatric conditions[3][7]. Because "methyl group transfer pathway" refers to a collection of processes and not a specific molecule, enzyme, or druggable target, it is **not considered a therapeutic target** per se—although individual enzymes (like DNA methyltransferases or protein methyltransferases) within these pathways are well-established drug targets in oncology and epigenetics[2][4][7]. **Note:** "Methyl group transfer pathways" are not a single molecular target, but rather a functional class or set of metabolic/epigenetic processes. For structured data systems, one should identify specific methyltransferase enzymes or methylation targets (e.g., DNA methyltransferase 1, protein arginine methyltransferase 5, etc.) for drug targeting or biomarker purposes.

Other names
Methylation pathwaySAM cycleTransmethylation pathwayOne-carbon metabolism
02

Biological functions

Epigenetic regulationGene expression regulationDNA methylationRNA methylationHistone modificationMetabolismProtein modification
03

Disease associations

CancerNeurodevelopmental and neuropsychiatric disordersCardiovascular diseaseMetabolic diseaseOther
04

Safety considerations

Altered methylation capacity (deficiency or excess) is associated with increased disease risk, such as cancer (hypermethylation of tumor suppressors), neural tube defects (folate/B12 deficiency), and toxicity from altered homocysteine
05

Biomarkers

HomocysteineSAM (S-adenosylmethionine) levelsSAH (S-adenosylhomocysteine) levelsMethylation status of DNA or histones

Beyond the preview

Go deeper on Methyl group transfer pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Methyl group transfer pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call